ChEMBL Resources

Resources:
ChEMBL
|
SureChEMBL
|
ChEMBL-NTD
|
ChEMBL-Malaria
|
The SARfaris: GPCR, Kinase, ADME
|
UniChem
|
DrugEBIlity
|
ECBD

Sunday, 25 October 2009

SMR Award Meeting: Recent Disclosures of Clinical Candidates - December 10th, London.


There is, what looks like, an excellent meeting in London, full details are on the SMR website. I hope I feel better by then.


SMR Award Meeting: Recent Disclosures of Clinical Candidates
10th December 2009
 
National Heart & Lung Institute, Kensington, London
Programme:

09.30
Registration and coffee
10.00
SMR Award lecture: The Discovery and development of Januvia, Dr. Ann Weber, Merck
(Introduction by - Rob Williams, 
Cancer Research UK)

Session 1 - Chair: Mark Searcy, University of East Anglia
11.00   
Chris Murray, Astex
From fragment to clinic - the discovery of the hsp90 inhibitor, AT13387.
11.45
George Muller, Celgene
The discovery of apremilast.
12.30
Lunch (Including SMR AGM 13.10-13.30)
Session 2 - Chair: Diane Coe, GSK
13.30
David Fox, Pfizer
The discovery of a second generation long-acting PDE5 inhibitor.

14.15
Simon Hodgson, GSK
The discovery of a dual H1/H3 antagonist for allergic rhinitis.

15.00
Tea
Session 3 - Chair: David Fox, Pfizer
15.30
Karl Gibson, Pfizer
The discovery of a progesterone receptor antagonist for endometriosis.
16.15
Mairi Gibson, GSK
Second generation EP1 antagonists for the treatment of pain.
17.00
Close

No comments: